Research Article| Volume 47, ISSUE 1, P1-6, July 1980

Download started.


Deficient intestinal absorption of l-tryptophan in progressive myoclonus epilepsy without Lafora bodies

      This paper is only available as a PDF. To read, Please Download here.


      l-Tryptophan was administered orally to 7 patients with progressive myoclonus epilepsy (PME) without Lafora bodies and 7 controls. Total and free plasma tryptophan were subsequently measured at intervals. Concentration of free tryptophan was equal in the two groups. Total tryptophan was significantly lower in PME patients and the difference became marked at 120 and 240 min after the oral dose. At the same time urinary excretion of indican rose in PME patients but not in controls but the change was not statistically significant. Urinary 5-HIAA excretion was a little lower in PME patients. The increase of 5-HIAA after administration of l-tryptophan was equal in both groups. Intravenous administration of l-tryptophan produced an equal increase of plasma concentrations in PME patients as in controls, measured at 2-h intervals. These findings suggest incomplete absorption of l-tryptophan through the intestinal tract in PME patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Eccleston E.G.
        A method for the estimation of free and total acid-soluble plasma tryptophan using an ultrafiltration technique.
        Clin. chim. Acta. 1973; 48: 269-272
      1. Klinische Labor. 1970; (11th edition, Merck,): 402
        • Klotz U.
        • Antonin K.H.
        Pharmacokinetics and bioavailability of sodium valproate.
        Clin. pharmacol. Ther. 1977; 21: 736-743
        • Korf J.
        • Valkenburgh-Sikkema T.
        Fluorimetric determination of 5-hydroxyindoleacetic acid in human urine and cerebrospinal fluid.
        Clin. chim. Acta. 1969; 26: 301-306
        • Koskiniemi M.
        Findings in routine laboratory examinations in progressive myoclonus epilepsy.
        Acta neurol. scand. 1975; 51: 12-20
        • Koskiniemi M.
        • Palo J.
        Urinary excretion of indican in progressive myoclonus epilepsy without Lafora bodies — The effect of sodium valproate.
        J. neurol. Sci. 1978; 39: 235-239
        • Koskiniemi M.
        • Donner M.
        • Majuri H.
        • Haltia M.
        • Norio R.
        Progressive myoclonus epilepsy — A clinical and histopathological study.
        Acta neurol. scand. 1974; 50: 307-332
        • MacIndoe J.
        • Turkington R.
        Stimulation of human prolactin secretion by intravenous infusion of l-tryptophan.
        J. Clin. Invest. 1973; 52: 1972-1978
        • Milne M.D.
        Some abnormalities of amino acid metabolism.
        in: Thompson R.H.S. Wootton I.D.P. Biochemical Disorders in Human Disease. 3rd edition. J. & A. Churchill, London1970: 593-595 (Chapter 16)
        • Milne M.D.
        • Crawford M.A.
        • Girao C.B.
        • Louchridge L.W.
        The metabolic disorder in Hartnup disease.
        Quart. J. Med. 1960; 115: 407-421
        • Tagliamonte A.
        • Gessa R.
        • Biggio G.
        • Vargiu L.
        • Gessa G.L.
        Daily changes of free serum tryptophan in humans.
        Life Sci. 1974; 14: 349-354